Ehle Benjamin, Hassan Mohamed, Le Uyen-Thao, Passlick Bernward, Grapatsas Konstantinos
Medizinische Fakultät, Albert-Ludwigs-Universität Freiburg, Klinik für Thoraxchirurgie, Universitätsklinikum Freiburg, Freiburg im Breisgau, Deutschland.
Zentralbl Chir. 2025 Feb;150(1):71-77. doi: 10.1055/a-2148-1207. Epub 2023 Sep 5.
There are only a few small published studies on pulmonary metastasectomy for urinary tract transitional cell carcinoma (TCC). In this study, we examined the long-term outcome and the prognostic survival factors associated with pulmonary metastasectomy of urinary tract TCC, as based on our centre's 20-year experience. Between 2000 and 2020, curative pulmonary metastasectomy was performed in 18 patients (14 males and 4 females). Clinical, demographical and surgical data were retrospectively analysed. The disease-free interval between treatment of the primary tumour and pulmonary metastasectomy ranged from one to 48 months. Survival analysis was conducted with the Kaplan-Meier method and log-rank test. The 3- and 5-year survival rates were 84.7% and 52.9%, respectively. Resection of solitary metastases was a positive and independent factor for survival (p = 0.04). Pulmonary metastasectomy of urinary tract TCC is associated with a favourable outcome and solitary metastasis is associated with long-term survival. Surgical resection of solitary pulmonary metastasis and repeated lung metastasectomy by pulmonary recurrence from a urinary tract TCC is feasible in selected patients.
关于尿路移行细胞癌（TCC）肺转移瘤切除术，仅有少数已发表的小型研究。在本研究中，基于我们中心20年的经验，我们探讨了尿路TCC肺转移瘤切除术的长期疗效及相关预后生存因素。2000年至2020年间，对18例患者（14例男性和4例女性）实施了根治性肺转移瘤切除术。对临床、人口统计学和手术数据进行了回顾性分析。原发性肿瘤治疗与肺转移瘤切除术之间的无病间期为1至48个月。采用Kaplan-Meier法和对数秩检验进行生存分析。3年和5年生存率分别为84.7%和52.9%。孤立性转移灶的切除是生存的积极且独立因素（p = 0.04）。尿路TCC肺转移瘤切除术预后良好，孤立性转移与长期生存相关。对于部分患者，手术切除孤立性肺转移灶以及因尿路TCC肺复发而再次进行肺转移瘤切除术是可行的。
